- Home
- LTBR vs VERV Comparison
LTBR vs VERV Comparison
Compare LTBR & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTBR
- VERV
- Stock Information
- Founded
- LTBR 1992
- VERV 2018
- Country
- LTBR United States
- VERV United States
- Employees
- LTBR N/A
- VERV N/A
- Industry
- LTBR Professional Services
- VERV Medicinal Chemicals and Botanical Products
- Sector
- LTBR Consumer Discretionary
- VERV Health Care
- Exchange
- LTBR Nasdaq
- VERV Nasdaq
- Market Cap
- LTBR 326.6M
- VERV 1.0B
- IPO Year
- LTBR N/A
- VERV 2021
- Fundamental
- Price
- LTBR $13.82
- VERV N/A
- Analyst Decision
- LTBR
- VERV Buy
- Analyst Count
- LTBR 0
- VERV 11
- Target Price
- LTBR N/A
- VERV $14.57
- AVG Volume (30 Days)
- LTBR 1.5M
- VERV 4.1M
- Earning Date
- LTBR 08-11-2025
- VERV 08-07-2025
- Dividend Yield
- LTBR N/A
- VERV N/A
- EPS Growth
- LTBR N/A
- VERV N/A
- EPS
- LTBR N/A
- VERV N/A
- Revenue
- LTBR N/A
- VERV $59,613,000.00
- Revenue This Year
- LTBR N/A
- VERV $47.32
- Revenue Next Year
- LTBR N/A
- VERV N/A
- P/E Ratio
- LTBR N/A
- VERV N/A
- Revenue Growth
- LTBR N/A
- VERV 271.44
- 52 Week Low
- LTBR $2.24
- VERV $2.87
- 52 Week High
- LTBR $17.70
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- LTBR 50.92
- VERV 9.97
- Support Level
- LTBR $12.58
- VERV $10.91
- Resistance Level
- LTBR $15.59
- VERV $11.25
- Average True Range (ATR)
- LTBR 1.27
- VERV 0.08
- MACD
- LTBR 0.02
- VERV -1.49
- Stochastic Oscillator
- LTBR 53.63
- VERV 0.00
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.